Aripiprazole Tablet
Product Images NDC 31722-819

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 31722-819). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A pharmacokinetic chart showing the effect of various other drugs on Aripiprazole indicated by fold change and 90% confidence intervals. The chart compares changes in AUC and Cmax relative to reference (without interacting drug) for inhibitors, inducers, gastric acid blockers, and other drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Figure2 (Figure2)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing dehydro-Aripiprazole fold change and 90% confidence intervals. It compares changes in AUC and Cmax relative to reference values without interacting drugs across various inhibitors, inducers, acid blockers, and other drugs, including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart depicting the effect of Aripiprazole on various other drugs. The chart shows fold change and 90% confidence intervals for pharmacokinetic parameters such as AUC, Cmax, and INR relative to reference without interacting drug. Drugs affected include dextromethorphan, warfarin enantiomers, omeprazole, lamotrigine, valproate, lithium, lorazepam, and venlafaxine, with fold changes mostly close to 1.0.*

FDA Label Image

Figure4 (Figure4)

A chart titled 'Aripiprazole Fold Change and 90% CI' illustrating pharmacokinetic changes (AUC, Cmax) in special populations versus reference groups. Categories compared include CYP2D6 metabolism status, gender, age, and severity of hepatic and renal impairment, showing fold changes with confidence intervals relative to reference values.*

FDA Label Image

Figure5 (Figure5)

A graph titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the effect of various factors on pharmacokinetic parameters AUC and Cmax. Factors compared include CYP2D6 poor vs. extensive metabolizer, gender, age groups, hepatic impairment severity, and severe renal impairment. Data points with error bars represent fold changes relative to reference values on the x-axis.*

FDA Label Image

Structure (Structure)

Chemical structure of aripiprazole, a small molecule compound used as an oral tablet for human prescription. The diagram shows the molecular framework representing the active ingredient aripiprazole.*

FDA Label Image

Aripi10mg30s

Aripiprazole 10 mg Tablets label from Camber Pharmaceuticals, Inc. The label includes dosage form as tablets, strength of 10 mg per tablet, quantity of 30 tablets, and mentions that it is for prescription use only (Rx only). The label also states the storage conditions and provides contact information along with a barcode.*

FDA Label Image

Aripi15mg30s

Aripiprazole Tablets USP 15 mg label from Camber Pharmaceuticals, Inc. The label states each tablet contains 15 mg of aripiprazole, with a package count of 30 tablets. It includes storage instructions, U.S. contact information, and notes the medication guide availability. The label references manufacturing by Hetero Labs Limited in India.*

FDA Label Image

Aripi20mg30s

Aripiprazole Tablets, USP 20 mg oral tablet label by Camber Pharmaceuticals, Inc. The label shows the drug name, strength, quantity of 30 tablets, and the NDC number 31722-829-30. It includes storage instructions, a barcode, manufacturer information, and a pharmacist note about dispensing the Medication Guide separately.*

FDA Label Image

Aripi2mg30s

Label for Aripiprazole Tablets USP 2 mg by Camber Pharmaceuticals, Inc. The label shows the NDC number 31722-819-30, indicates the package contains 30 tablets, and includes directions to see the package insert for full prescribing information. It features storage instructions and a U.S. contact number, along with a barcode and manufacturer details.*

FDA Label Image

Aripi30mg30s

Label for Aripiprazole Tablets, USP 30 mg by Camber Pharmaceuticals, Inc. The label shows the NDC 31722-830-30, contains 30 tablets, and includes storage instructions at 20 to 25°C. It also provides a pharmacist medication guide notice, a barcode, and manufacturer details including Hetero Labs Limited in India.*

FDA Label Image

Aripi5mg30s

Aripiprazole Tablets USP 5 mg oral tablets packaging label from Camber Pharmaceuticals, Inc. The label includes NDC 31722-820-30 and states the package contains 30 tablets. It specifies storage instructions, a pharmacist medication guide notice, a barcode, and manufacturer details including Camber Pharmaceuticals in New Jersey and Hetero Labs Limited in India.*

FDA Label Image

Camber Logo

FDA Label Image

Figure-6 (Figure 6)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over time between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The number of subjects at risk is displayed below the x-axis for each group at multiple time points.*

FDA Label Image

Figure 7

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over time in days from randomization for Aripiprazole and placebo groups. The solid line represents Aripiprazole, and the dashed line represents placebo. The chart includes the number of subjects at risk at various time points up to 182 days.*

FDA Label Image

Figure 8

A Kaplan-Meier plot showing the proportion with relapse over days from randomization comparing Aripiprazole and placebo groups. The x-axis represents days from randomization up to 364 days, with numbers of subjects at risk listed below. The y-axis shows the proportion with relapse from 0 to 1. The plot contains two curves: a solid line for Aripiprazole and a dashed line for placebo, illustrating their relapse proportions over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.